Share
Behind the Breakthroughs
Hussam Al Kateb: Inside Mayo Clinic’s Genomic Diagnostics Revolution
Ep. 53
•
Mayo Clinic Laboratories’ new whole-transcriptome RNA sequencing assay expands the detection of clinically significant gene fusions across solid tumors, helping refine cancer diagnoses and inform targeted treatment decisions. Hussam Al Kateb, PhD, co-director of Mayo Clinic’s Clinical Genomics Lab, takes us behind the scenes of a major reference laboratory to explore the challenges of developing advanced genomic diagnostics, keeping pace with scientific discovery, and translating technological breakthroughs into precision oncology.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
Medicine is full of breakthroughs. Most don't become medicine. Behind the Breakthroughs explores scientific ideas that could change how we diagnose and treat disease—and what it will take for them to work. Host Jonathan D. Grinstein, PhD, a scientist-turned-journalist, speaks with the researchers, physicians, and entrepreneurs building the next generation of genetic medicines, diagnostics, AI, precision therapeutics, and biotechnology.
More episodes
View all episodes
54. Ryan Beal: Getting Under Cancer's Skin
51:49||Ep. 54Dyve Biosciences is developing a technology to deliver drugs through the skin that conventional transdermal approaches cannot accommodate. Its lead oncology program, DV800, targets tumor acidity, a longstanding therapeutic challenge. In this episode of Behind the Breakthroughs, CEO Ryan Beal, MD, discusses the technology, its potential in cancer treatment, and how his own cancer experience reshaped his approach to drug development.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)52. Matt Begemann: The Cancer-Killing CRISPR
46:26||Ep. 52What began as a search for plant-friendly CRISPR tools led Matt Begemann, PhD, and colleagues to Cas12a2, or CasCLEAR, an unusual system that can trigger broad nucleic acid damage after recognizing an RNA target, creating potential applications in cancer therapy, diagnostics, and antimicrobials. With early studies showing promise against cancer-causing mutations, Begemann’s story highlights both the challenges of translating Cas12a2 into therapies and the value of pursuing unexpected scientific discoveries.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)51. Wei-Wu He: Craig Venter’s Legacy and the Future of Human Longevity
01:02:00||Ep. 51Human Longevity executive chairman Wei-Wu He discusses how the integration of genomics, advanced imaging, and artificial intelligence could transform disease prediction and personalized preventive medicine. Reflecting on Craig Venter’s legacy, he explores the challenges of democratizing precision medicine and the quest to extend human healthspan by identifying and intervening in disease before symptoms emerge.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)50. Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
59:24||Ep. 50Roche’s AXELIOS sequencer, Alzheimer’s blood test, and push to automate mass spectrometry point to a broader strategy of making advanced diagnostics routine. Whether AXELIOS can meaningfully challenge Illumina’s sequencing dominance, however, remains an open question.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)49. Ken Greenberg: Can Ultrasound Shatter the Gene Therapy Delivery Bottleneck?
51:45||Ep. 49Gene therapy’s biggest bottleneck remains delivery: getting increasingly sophisticated genetic medicines safely into the right cells. SonoThera is taking a radically different approach, using ultrasound and microbubbles instead of viral vectors and nanoparticles, which could allow for larger payloads, repeat dosing, and precise tissue targeting. The key question is whether this seemingly too-good-to-be-true approach can work in humans after promising results across multiple organs in animals.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)48. David Thaisrivongs: Goldilocks and the First Oral PCSK9 Inhibitor
42:00||Ep. 48Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)47. Beaubrun and Acharya: No Antibiotic Without a Diagnostic
57:29||Ep. 47Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of Behind the Breakthroughs, Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing Enterobacterales (CPE)—dangerous, last-resort antibiotic-resistant bacteria that are spreading rapidly in hospitals. They also explore the scientific, clinical, and policy challenges of making rapid diagnostics a routine part of healthcare worldwide.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)46. Amit Etkin: Precision Psychiatry’s Future Isn’t Genomics—It’s Brain Activity
01:00:32||Ep. 46For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of Behind the Breakthroughs, Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biologically defined patient populations could make precision psychiatry routine, improving outcomes and changing how psychiatric disorders are diagnosed and treated.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)